Tag: Phase 3 PRECISION

Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension

Rhythm by 0 comments

Aprocitentan is an investigational antihypertensive drug with a novel mechanism of action RARITAN, N.J., Nov. 7, 2022 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which […]

Continue Reading →